Presenter（主持人）: Deven Kam Kuen LO（罗锦权）

- Director of International Intangible Assets Institute (IIAI)
  （国制无形资产协会董事）

- Co-founder and CEO of B.Y. QUANTITATIVE MEDICINE LIMITED
  (以恩定量医学有限公司联合创始人及首席执行官)

Tel: (852) 9142 3169
Email: deven.byqm@gmail.com

公司资料（Company Information）~1

愿景（Vision）：

通过人工智能促进生物医学研究和医疗保健

(Promote biomedical research and healthcare through artificial intelligence)

任务 (Mission)：

寻找有关疾病的重要证据，并使其可用于医疗保健提供者并为患者提供最合适的解决方案

(Continue to look for important biological evidence about the diseases and make it available for medical and health care providers to treat patients with the most suitable therapeutic solutions)

公司资料 (Company Information)~2

- 全球第一家建立基因与基因之间互动分析平台的公司 。(We are the first company to establish a quantitative biochemistry platform for the analysis of genes interaction.)

- 自主开发的深度学习服务模型提供一个综合和结构性的策略来确定与核磷蛋白(NPM1）相关的癌症和其他疾病的基因共表达网络。(Our self-developed deep learning service model provides a comprehensive and structural strategy to determine the gene co-expression network of cancers and other diseases related to Nucleophosmin (NPM1/B23).

- 过去重点放在癌症的相关研究上。 已经已成功取得为乳腺癌、肝癌（病毒感染)、大肠癌、肺癌等相关的癌症复发预测、癌症阶段性评估及区分低风险和高风险患者等重要医学数据。(In the past, our focus has been on cancer-related research. We have successfully obtained important medical data such as breast cancer, liver cancer (viral infection), colorectal cancer, lung cancer and other related cancer recurrence prediction, cancer stage assessment and distinguishing low-risk and high-risk patients etc.)

公司资料 (Company Information)~3

- 我们的人工智能深度学习服务模型具有足够的伸延性并可扩展到其他疾病，例如病毒感染性疾病（如SARS相关冠状病毒、肝炎病毒（HBV, HCV, HDV）和艾滋病病毒(HIV)）、退化性疾病 (如心血管疾病、骨关节炎、阿兹海默病等)及代谢性疾病(如糖尿病等)，并对基因和表型之间的相互作用进行量化，可以看到基因之间互动关系、发病机理和原因、评估风险、药物反应（中西药）和建议。

（Our artificial intelligence deep learning service model has sufficient scalability and can be extended to other diseases, such as viral infectious diseases (such as SARS-related coronavirus HBV, HCV, HDV and HIV), and degenerative diseases (such as cardiovascular disease), Osteoarthritis, Alzheimer, etc.), and metabolic disordering diseases (such as diabetes, etc.). This model quantifies the interaction between genotypes and phenotypes so that the interaction between genes can be seen, diseases' pathogenesis and causes can be known, risks assessment can be made, drug responses and resistance can be known for treatment strategy and recommendations (both Chinese and Western medicine).

我们提供的服务（The services we provide）

i）提供高精准、关键和决定性生物学信息,可在宏观角度揭示基因网络互动，以用于疾病早期发现和诊断及预测癌症的治疗反应，预后和生存机率。
（High accuracy, critical, and conclusive biological information to unravel the macroscopic interconnected genetic networks for early detection and diagnosis of the diseases and prediction of the treatment response, prognosis, and survival for cancers.）

ii）提供重要生物学信息（疾病机理和基因发病机理）用于药物开发，生物检测开发，商业化，临床前研究，临床研究，临床试验管理和药物警戒。
（Critical biological information (diseases mechanism and genetic pathogenesis) for pharmaceutical development, biologic assay development, commercialization, preclinical research, clinical research, clinical trials management, and pharmacovigilance.）

定量医学基因共表达平台（Quantitative Biomedicine Gene Co-expression Platform）

分析20,000基因互动关系及量化以亿计的基因组群互動。
（Analyze 20,000 gene interactions & quantify billions of gene group interactions）

我们建立 (We build):
定量医学基因共表达平台
Quantitative Biomedicine Gene Co-expression Platform

大数据分析+ 多种疾病临床医学数据 (AI + multiple diseases)*

- 预后和治疗评估及疾病控制 (Prognostic and Treatment Evaluation)

- 药物筛选及开发 (Drug Screening & Development)

- 早期诊断和复发预测 (Early Diagnosis, Drugs Response, & Relapse Prediction)

* 癌症、病毒感染性疾病、退化性疾病、代谢性疾病 ……
(Cancers, Viral Infectious, Degenerative & Metabolic Disordering diseases ...)

定量医学基因共表达平台应用
（Quantitative Biomedicine Gene Co-expression Platform Application）

過往，没有大数据基因共表达分析平台以前
所有检测、诊断都是**盲目的**

Were blind

治疗结果完全取决医生的技能、
手术的质量和经验
(The result of treatment depends entirely on the doctor’s skills., the quality and experience of the operation)

现在，我们看到了 (Now, we can see)

How ill / well we are

我们有多病/有多好

How the medicine works for us

药物如何为我们服务
例如，核糖体的生物合成，DNA修复，
免疫反应，MAPK，Wnt，氧化磷酸化等

If and how we are cured

治疗方案

WHY FINLAND?

芬兰优势

1 Global Innovation Index 2016 / 2 World Economic Forum, The Global Competitiveness Report 2016-2017 / 3 FDI attractiveness scoreboard, Copenhagen Economics 2016 4 The Fund for Peace, Fragile States Index 2016 / 5 Grant Thornton, Global Dynamism Index 2015 / 6 Bloomberg, Bloomberg 2017 Innovation Index 7 Education First (EF), The world's largest ranking of countries by English skills / 8 UN 2018 World Happiness Report / 9 The Consumer Technology Association (CTA)™ 2018

Focus Industries (芬兰的优势行业)

Bio-economy
(生物质经济)

- Biofuels & chemicals (生物燃料)
- Advanced Biomaterials (先进生物材料)
- Wood construction (木业)

"Kick start your bio-based business."

Cleantech
(清洁技术)

- Smart grid (空气净化)
- Energy storage (储能)
- Renewable energy (可再生能源 智能电网)

"Greenest country in the world."

Health
(医疗&健康)

- Pharma (新药研发)
- Health tech (医疗器械)
- Diagnostics (诊断)
- Digital health (数字医疗)

"A living lab for global cures."

ICT / Digi
(ICT&数字化)

- Augmented Intelligence (智能制造)
- Connectivity & 5G (人工智能 5G)
- Augmented / Virtual Reality (增强/虚拟现实)
- Financial tech (金融科技)
- Cybersecurity(网络安全)

"Brainpower for your next Big Thing."

Travel
(旅游)

- Tourism operators (酒店)
- Tourism related real estate investors(度假村)

"World's 3rd best travel destination by Lonely Planet"

Invest in Finland 芬兰投资署

- Established in 1992, Invest in Finland (IIF) is a part of Business Finland
- Finnish government organization promoting direct foreign investment.
- IIF China team consists of local experts based in China to be closer to the Chinese investors
- 芬兰投资署（Invest in Finland，简称IIF）成立于1992年，隶属于芬兰国家商务促进局（Business Finland）
- 芬兰国家促进外国直接投资的政府机构
- 芬兰投资署有中国团队在中国为中国投资者提供贴心服务。

芬兰投资署为外国公司提供的服务 Our Tailored Services

- 数据收集与分析 Data Collection and Analysis
- 机会分析 Opportunity Analysis
- 入市方案 Entry alternatives
- 关系网拓展 Matchmaking
- 选址管理 Location management
- 企业设立 Setting up a business

高度保密且免费！ **Our comprehensive services are confidential and complimentary！**

Footnote

The above presentation slides with respect to Finland were excerpted from the presentation of “Dr. Mika Klemettinen - The Finnish innovation system: Why Finland is a globally leading country in innovation? What the greenest, happiest and one of the technologically strongest country has to offer?”, under the topic of “Local Policies in China and Europe for Collaboration”, presented on December 10, 2020.

This presentation material can be found at http://www.iiainstitute.org/

谢谢